Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced in the stomach.
### Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis
* Healing of erosive esophagitis
* Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome
### Adult Dosing
* **GERD/Erosive Esophagitis (Healing):** 40 mg orally or intravenously once daily for up to 8 weeks.
* **GERD (Maintenance):** 20 mg orally once daily. If needed, may increase to 40 mg once daily.
* **Hypersecretory Conditions:** 40 mg orally or intravenously twice daily. Doses may be increased as needed. Usual maximum: 120 mg every 8 hours.
### Pediatric Dosing
* **GERD (Erosive Esophagitis):**
* **1 to 5 years:** 10 mg orally once daily for up to 8 weeks.
* **5 to 12 years:** 20 mg orally once daily for up to 8 weeks.
* **12 years and older:** 40 mg orally once daily for up to 8 weeks.
* Dosing for pathological hypersecretory conditions in pediatric patients is not well-established and should be individualized.
### Dose Adjustments
* No dose adjustment is typically required for hepatic impairment, but caution is advised, and the lowest effective dose should be used.
* No dose adjustment is typically required for renal impairment.
### Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
### Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness.
* **Serious:** *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia (potentially severe), systemic lupus erythematosus, fundic gland polyps.
### Key Drug Interactions
* **Drugs dependent on gastric pH for absorption:** Ketoconazole, itraconazole, iron salts, delavirdine, ritonavir. Pantoprazole can decrease absorption.
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Monitor for potential interactions with drugs metabolized by this enzyme (e.g., clopidogrel, voriconazole).
### Monitoring
* Monitor for signs and symptoms of hypomagnesemia, especially with prolonged therapy (>1 year) or concomitant use of other drugs that cause hypomagnesemia (e.g., diuretics).
* Monitor for bone fracture risk in patients at risk.
* Consider monitoring vitamin B12 levels with long-term PPI therapy.
* Monitor for *C. difficile* infection symptoms.
### Clinical Pearls
* Pantoprazole is available in oral and intravenous formulations.
* Intravenous administration may be preferred in patients unable to take oral medications or with significant nausea/vomiting.
* Long-term use of PPIs is associated with increased risk of fractures, hypomagnesemia, and *C. difficile* infection. Use the lowest effective dose for the shortest duration necessary.
* The 20 mg dose is typically used for maintenance therapy of GERD.
* For hypersecretory conditions, dosing is highly individualized and may require higher doses and more frequent administration.
***
*This information is intended for clinical decision-making and does not replace the need to consult the official prescribing information or local protocols. Always verify current drug information before prescribing.*
